Spyre Therapeutics (SYRE) Non Operating Income (2015 - 2026)
Spyre Therapeutics posted quarterly Non Operating Income of -$30.4 million for Q1 2026, down 445.81% year-on-year from $8.8 million in Q1 2025, and little changed on a QoQ basis from -$30.2 million in Q4 2025.
Spyre Therapeutics (SYRE) has 12 years of Non Operating Income data on file, last reported at -$30.4 million in Q1 2026.
- For the quarter ending Q1 2026, Non Operating Income fell 445.81% year-over-year to -$30.4 million; the trailing twelve-month figure through Mar 2026 stood at -$15.6 million (down 257.72% YoY), and the FY2025 full-year result was $29.5 million, up 4818.03% from the prior year.
- Non Operating Income for Q1 2026 stood at -$30.4 million, roughly flat from -$30.2 million in the prior quarter.
- Across five years, Non Operating Income topped out at $45.7 million in Q3 2025 and bottomed at -$98.8 million in Q4 2023.
- The 5-year median for Non Operating Income is $109000.0 (2022), against an average of -$5.7 million.
- Peak annual rise in Non Operating Income reached 6860.0% in 2023, while the deepest fall reached 26230.95% in 2023.
- A 5-year view of Non Operating Income shows it stood at $378000.0 in 2022, then slumped by 26230.95% to -$98.8 million in 2023, then surged by 120.75% to $20.5 million in 2024, then sank by 247.57% to -$30.2 million in 2025, then slipped by 0.38% to -$30.4 million in 2026.
- The last three Non Operating Income figures came in at -$30.4 million (Q1 2026), -$30.2 million (Q4 2025), and $45.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Spyre Therapeutics | 5.55 Bn | 5.55 Bn | - | -30.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -30.36 Mn |
| Dec 31, 2025 | -30.24 Mn |
| Sep 30, 2025 | 45.71 Mn |
| Jun 30, 2025 | -656,000.00 |
| Mar 31, 2025 | 8.78 Mn |
| Dec 31, 2024 | 20.49 Mn |
| Sep 30, 2024 | -18.80 Mn |
| Jun 30, 2024 | -610,000.00 |
| Mar 31, 2024 | 3.95 Mn |
| Dec 31, 2023 | -98.78 Mn |
| Sep 30, 2023 | 2.34 Mn |
| Jun 30, 2023 | -8,000.00 |
| Mar 31, 2023 | 348,000.00 |
| Dec 31, 2022 | 378,000.00 |
| Sep 30, 2022 | 312,000.00 |
| Jun 30, 2022 | 109,000.00 |
| Mar 31, 2022 | 5,000.00 |
| Dec 31, 2021 | 96,000.00 |
| Sep 30, 2021 | 12,000.00 |
| Jun 30, 2021 | -52,000.00 |
| Mar 31, 2021 | -31,000.00 |
| Dec 31, 2020 | 62,000.00 |
| Sep 30, 2020 | 2,000.00 |
| Jun 30, 2020 | -19,000.00 |
| Mar 31, 2020 | 294,000.00 |
| Dec 31, 2019 | 414,000.00 |
| Sep 30, 2019 | 573,000.00 |
| Jun 30, 2019 | 603,000.00 |
| Mar 31, 2019 | 490,000.00 |
| Dec 31, 2018 | 1.15 Mn |
| Sep 30, 2018 | 326,000.00 |
| Jun 30, 2018 | -7,000.00 |
| Mar 31, 2018 | -17,000.00 |
| Dec 31, 2017 | -7,000.00 |
| Sep 30, 2017 | 124,000.00 |
| Jun 30, 2017 | -12,000.00 |
| Mar 31, 2017 | 84,000.00 |
| Dec 31, 2016 | -184,000.00 |
| Sep 30, 2016 | 63,000.00 |
| Jun 30, 2016 | 65,000.00 |
| Mar 31, 2016 | -6,000.00 |
| Dec 31, 2015 | -12,000.00 |
| Sep 30, 2015 | -1,000.00 |
| Jun 30, 2015 | 5,000.00 |
| Mar 31, 2015 | 1,000.00 |